Envisioning a new future for patients with inherited retinal diseases

Groundbreaking gene therapy

 

Groundbreaking gene therapy built by and for patients with rare inherited retinal diseases (IRD)

Backed by Foundation Fighting Blindness’s venture arm, the Retinal Degeneration Fund, Opus Genetics combines unparalleled insight and commitment toward patient need with wholly owned programs in numerous rare retinal diseases to create important new AAV-based retinal gene therapies for patients.

Patient-Guided
Patient-Guided
Gene Therapy Pipeline
Gene Therapy Pipeline
Unique Approach
Unique Approach

Preserving vision

Targeting mutations in genes causing inherited retinal diseases

Opus Genetics’ focus is on developing and advancing treatments to address mutations in genes that cause loss of vision, including bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP), while building out an engine to efficiently solve for many other inherited blinding conditions. Read more about our approach.

Human eye with blowup showing the detail of the structure of the retina

“I’ve dedicated my career to the research and development of treatments for blinding diseases, and I’m eager to continue to build on this work with Opus.”

—Dr. Jean Bennett, scientific founder

Jean Bennett

August 21, 2024 Opus Genetics Receives Rare Pediatric Disease Designation from the U.S. FDA for Ocular Gene Therapy OPGx-LCA5 to Treat Rare Inherited Retinal Disease LCA5
June 13, 2024 Opus Genetics Announces $1.7 Million in Project-based Funding from the Foundation Fighting Blindness to Support Two Preclinical Programs
June 5, 2024 Department of Health – Abu Dhabi and Opus Genetics Announce Collaboration to Advance Ground-Breaking Gene Therapy Research for Inherited Retinal Diseases
"Hope is what we received when we heard about the potential treatment for Braydon’s rare inherited retinal disease. We are very excited that Opus’ focus is on helping people with rare eye diseases!"